Research Analysts Offer Predictions for BMY Q2 Earnings

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Investment analysts at William Blair decreased their Q2 2025 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a research report issued on Monday, July 14th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $1.03 per share for the quarter, down from their prior forecast of $1.52. William Blair has a "Market Perform" rating on the stock. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the previous year, the firm earned ($4.40) earnings per share. The firm's revenue for the quarter was down 5.6% on a year-over-year basis.

A number of other research firms have also weighed in on BMY. The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Piper Sandler started coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. UBS Group cut their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Argus upgraded Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Jefferies Financial Group dropped their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of "Hold" and a consensus price target of $57.69.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $46.47 on Wednesday. The company's fifty day simple moving average is $47.43 and its two-hundred day simple moving average is $53.10. Bristol Myers Squibb has a 12-month low of $40.09 and a 12-month high of $63.33. The firm has a market cap of $94.57 billion, a PE ratio of 17.41, a price-to-earnings-growth ratio of 2.42 and a beta of 0.36. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently bought and sold shares of BMY. Pinney & Scofield Inc. purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new position in Bristol Myers Squibb during the 4th quarter valued at approximately $26,000. Transce3nd LLC bought a new position in Bristol Myers Squibb during the 4th quarter valued at approximately $28,000. Global Wealth Strategies & Associates raised its stake in Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new stake in Bristol Myers Squibb in the first quarter worth $31,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.07% of the stock is owned by corporate insiders.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.34%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.